Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Factors affecting response of chemotherapy in women with ovarian cancer
J. Lubin1,*, A. Markowska2, P. Knapp3
1 Clinic of Oncology in Poznań, Departament of Gynecology, Poznań
2 Institute of Gynecology and Obstetrics, Poznań; 3University Hospital in Białystok, Departament of Gynecology, Białystok (Poland)
Eur. J. Gynaecol. Oncol. 2012, 33(6), 644–647;
Published: 10 December 2012
Chemotherapy plays an important role in the treatment of ovarian cancer. Patients’ response to chemotherapy is determined by a variety of acknowledged factors, but one might expect that many of them are yet to be described. The aim of this paper was to present the most essential yet still to be generally assessed in clinical practice, factors, which include: E-cadhedrin, hypoxia inducible factor α, survivin, COX-2, clusterin, BRCA1 protein, TP53 protein, YY1 protein, multidrug resistance protein, and interleukin-8.
Factors affecting chemotherapy